Registration Filed For Sale Of Volvo P&U Shares

23 June 1996

Pharmacia & Upjohn has confirmed that, at Volvo's request, it has filed a registration statement with the US Securities and Exchange Commission in relation to the divestment of shares in the company held by Volvo.

Volvo has a 13.7% stake in P&U, representing around 69.7 million shares. It is understood that the registration made by P&U at the SEC will allow Volvo to sell up to 52.9 million shares; around 66% of its total stake. In a Wall Street Journal report, analysts suggested that the market could not swallow the almost 14% stock divestment in one go. However, Volvo has made a commitment to severe its links with P&U by the end of the current year.

One analyst said that P&U must be happy to say goodbye to its major shareholder, as Volvo has already hurt the deal that management wanted. It will give the company more control over its own destiny.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight